NEW YORK, April 23-Biochip company Nanogen has secured a license from the Australian firm Genetic Technologies Limited for access to non-coding DNA analysis patents, the companies said yesterday.
The license, which took effect April 12, is not exclusive, and is limited to human research and diagnostics.
Genetic Technologies said that Nanogen is paying the company cash and securities worth approximately A$620,000 (US $334,207) as an issue fee for the license.
Genetic Technologies recently granted a much broader license to Sequenom for its non-coding DNA patents, and is currently in discussions with other major United States biotech companies.
The company, which is based in Melbourne, boasts Australia's largest DNA paternity testing lab. In addition, it holds a range of international patents on non-coding (intron) DNA analysis and non-coding genomic mapping.